ALTHOUGH INVESTIGATION INTO BIOLOGICAL RESPONSE MODIFIERS HAS INCREASED RECENTLY, MOST OF THE EFFORT HAS BEEN TOWARDS POTENTIATING THE HOST'S CELL-MEDIATED IMMUNITY.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$48,529.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
3008
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
American Biotechnology Co., In
7658 Standish Place, Suite 107, Rockville, MD, 20855
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PETER E. MAXIM
PRINCIPAL INVESTIGATOR
(301) 294-9553
Business Contact:
() -
Research Institution:
n/a
Abstract
ALTHOUGH INVESTIGATION INTO BIOLOGICAL RESPONSE MODIFIERS HAS INCREASED RECENTLY, MOST OF THE EFFORT HAS BEEN TOWARDS POTENTIATING THE HOST'S CELL-MEDIATED IMMUNITY. DATA ACCUMULATED BY OUR LABORATORIES INDICATE THAT THE METHYLFURYLBUTYROLACTONE (MFBL) CLASS OF COMPOUNDS REPRESENTS NEW SYNTHETIC IMMUNE RESPONSE MODIFIERS CAPABLE OF ACTIVATING SEVERAL COMPONENTS OF IMMUNE RESPONSE WITH NEGLIGIBLE TOXICITY TO THE HOST. THIS PROPOSAL DESCRIBES RESEARCH DESIGNED TO ANALYZE ONE ASPECT OF THE IMMUNOSTIMULATORY ACTIVITY OF MFBLS, THE ABILITY TO STIMULATE ANTIBODY PRODUCTION. PHASE I RESEARCH WILL CONCENTRATE ON THE OPTIMIZATION OF TREATMENT REGIMENS AND THE EVALUATION OF THE RANGE OF ACTIVITY OF THE DRUGS TOWARD THE PRIMARY AND SECONDARY ANTIBODY RESPONSE TO T-DEPENDENT AND T-INDEPENDENT ANTIGENS. WE FURTHER INTEND TO STUDY THE EFFECT OF MFBL IN VIVO ON THE IMPROVEMENT OF THE QUALITY AND QUANTITY OF ANTIBODY PRODUCTION IN MICE AS THAT RELATES TO MONOCLONAL ANTIBODY TECHNOLOGY. IN ADDITION, WE WILL ASSESS MURINE IN VITRO ANTIGEN SENSITIZATION

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government